Effect of pioglitazone on renal function amelioration by measurement of cystatine C levels in the type 2 diabetic patients

Effect of pioglitazone on renal function amelioration by measurement of cystatine C levels in the type 2 diabetic patients - Effect of pioglitazone on renal function amelioration in the type 2 diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000689

Enrollment

Registered

2008-03-31

Start date

2007-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

pioglitazone 15-30mg/day metformin 750mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)The patients who were diagnosed as type 2 diabetic nephropathy (stage II-IV) 2)Less than HbA1c 9.0 %

Exclusion criteria

Exclusion criteria: 1)The patient that it is already taken thiazolidinedione. 2)The patient with serious liver functional dysfunction. 3)Gravida or the patient with pregnant likelihood. 4)It is the patient with irritation for thiazolidinedione.

Design outcomes

Primary

Measure	Time frame
cystatine C, creatinine clearance, albumin extcretion rate, creatinine	—

Secondary

Measure	Time frame
general biochemical tests, HOMA-R, fasting blood insulin, serum resistin, CRP, adiponectin, leptin levels	—

Countries

Japan

Contacts

Public ContactEITARO NAKASHIMA

Nagoya University Hospital Department of Endocrinology and Diabetes

eitaro@med.nagoya-u.ac.jp052-744-2142

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026